about
Cardiovascular action of a cardioselective Ca(2+)channel blocker AH-1058 in conscious dogs assessed by telemetry.Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones.Role of P-glycoprotein in regulating cilnidipine distribution to intact and ischemic brain.Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias.No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.Clinical assessment of arterial stiffness with cardio-ankle vascular index: theory and applications.Asymmetric synthesis and biological evaluations of (+)- and (-)-6-dimethoxymethyl-1,4-dihydropyridine-3-carboxylic acid derivatives blocking N-type calcium channels.Effects of S(+)-efonidipine on the rabbit sinus node action potential and calcium channel subunits Ca(V)1.2, Ca(V)1.3 and Ca(V)3.1.Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.Analysis of arrhythmogenic profile in a canine model of chronic atrioventricular block by comparing in vitro effects of the class III antiarrhythmic drug nifekalant on the ventricular action potential indices between normal heart and atrioventriculaDiscovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity.Famotidine does not induce long QT syndrome: experimental evidence from in vitro and in vivo test systems.H₂receptor-mediated positive inotropic effect of histamine in neonatal guinea-pig left atria.Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation.Effect of NIP-142 on potassium channel alpha-subunits Kv1.5, Kv4.2 and Kv4.3, and mouse atrial repolarization.Cardiovascular effects of azelnidipine in comparison with those of amlodipine assessed in the halothane-anaesthetized dog.Famotidine neither affects action potential parameters nor inhibits human ether-a-go-go-related gene (hERG) K+ current.Clobutinol delays ventricular repolarization in the guinea pig heart: comparison with cardiac effects of HERG K+ channel inhibitor E-4031.Antiarrhythmic and cardiohemodynamic effects of a novel Ca(2+) channel blocker, AH-1058, assessed in canine arrhythmia models.In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models.Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs.Antisympathetic and hemodynamic property of a dual L/N-type Ca(2+) channel blocker cilnidipine in rats.Cardiac effects of clinically available Kampo medicine assessed with canine isolated, blood-perfused heart preparations.Cardiac effects of a selective rho-associated kinase inhibitor, Y-27632, assessed in canine isolated, blood-perfused heart preparations.Cardiac effects of salvia miltiorrhiza/dalbergia odorifera mixture, an intravenously applicable Chinese medicine widely used for patients with ischemic heart disease in China.Effects of the fluoroquinolone antibacterial drug ciprofloxacin on ventricular repolarization in the halothane-anesthetized Guinea pig.Cardiovascular and adenylate cyclase stimulating effects of colforsin daropate, a water-soluble forskolin derivative, compared with those of isoproterenol, dopamine and dobutamine.Cardiovascular effects of Y-27632, a selective Rho-associated kinase inhibitor, assessed in the halothane-anesthetized canine model.Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome.Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells.Effects of class I antiarrhythmic drugs on the digitalis-induced triggered activity arrhythmia model: a rationale for the short-term use of class I drugs against triggered arrhythmias.Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models.Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model.Cardiovascular effects of an L/N-type Ca2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs.The conventional antihistamine drug cyproheptadine lacks QT-interval-prolonging action in halothane-anesthetized guinea pigs: comparison with hydroxyzine.Electropharmacological effects of a spironolactone derivative, potassium canrenoate, assessed in the halothane-anesthetized canine model.The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart.Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs.Involvement of the Na(+)/Ca(2+) exchanger in the automaticity of guinea-pig pulmonary vein myocardium as revealed by SEA0400.
P50
Q31925786-DA759EFB-4671-4E1E-9845-BA14FB18E3C8Q35026580-945A675F-3C71-49DF-8379-57FBFE0390B8Q35074997-72FAF005-7F95-4151-B8DF-7770E6841355Q35545379-9BFE484D-3045-4924-BED5-FBCE59001A82Q36054313-FC3120E3-915B-492B-AA78-3F0A0CC33EACQ37434477-480D92C4-A4F9-4875-8A16-EA4416A9169AQ38538517-C9B1DA00-FE13-44AB-B549-095ACD2EEA3EQ39554206-DE2F0890-DA94-4B23-9FBB-E3769321079AQ39653136-BCA98A59-5F9D-404E-9CE3-449E7804FBD2Q39958637-117CF162-A605-4917-9271-092C2568142AQ40243953-B7EF958A-08B8-43F9-8220-A1C0CA227098Q40292380-81953191-2770-47F5-909E-25C320F22F0AQ40658056-3F223BE4-F2F6-44C0-97A6-004033A9B080Q42783666-31268FE1-4D74-49EC-9DE3-07A17EB94FB2Q43054873-C844F8E7-C98D-4F15-B055-520B04E14F3FQ43203152-4BCFA6B5-A13C-45A3-BB9C-69A92040C118Q43244357-EFA8CD56-E599-4877-B7AB-00FAFDD1C588Q43268320-51FAE6A4-E0B7-496A-AAFD-4C2107F22E45Q43273356-BC71E170-1FAC-4403-8E29-9DCE79DEBD63Q43504135-805E558D-54E6-4F6C-92A2-F4B218097170Q43776554-9DD02440-EB82-4B41-B30A-B0B0C7E04BDCQ43798819-DB28D335-EF30-4A62-B0F7-8BE44508B137Q43832423-F4EF2AEE-F2B8-4E82-A0FE-3F5A90ED0D6CQ43956823-E74098C2-0EB6-4B11-9941-48750DAD90AEQ43956844-A6DB47DC-673D-4DDB-96AE-6D0B6ABBD5FBQ43985747-70040470-6509-4804-A137-8AEBFCEECD81Q44005287-580CEB6E-919E-4173-8DE0-D1E7AD1286C4Q44260671-FAAA08AA-5334-4586-AC7F-C51A1980B9F5Q44283510-BB1F25D9-196B-46C7-9EB1-312D0DE4CAB7Q44582057-25567375-78C8-4EED-916E-D2870DA6563EQ44657561-B462F15A-29F3-40D1-8C48-1259663AACEBQ44699660-E756482E-9DBD-4BCB-A788-940960D6262DQ44835408-1F3CDAD6-6E09-4B5B-AAFE-AB7A949B2A9FQ45038916-4F260528-D8CD-47DF-984E-9F023724CD2BQ45113327-B3731DAD-520B-41A4-BA4B-06D18C51C891Q45131856-853E14B1-EB93-459C-B188-EDE8902945DEQ45187434-3FE13400-0773-483E-B4C8-AE3E147587CEQ45227838-3C0981DF-2B1B-4579-9464-2D8E3A2B411CQ45941501-9C16B997-A784-4F09-B3D2-33C10684B8A1Q46021059-C1A88AF8-54AF-4649-BB93-FE6B13B65B94
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Akira Takahara
@ast
Akira Takahara
@en
Akira Takahara
@es
Akira Takahara
@nl
type
label
Akira Takahara
@ast
Akira Takahara
@en
Akira Takahara
@es
Akira Takahara
@nl
prefLabel
Akira Takahara
@ast
Akira Takahara
@en
Akira Takahara
@es
Akira Takahara
@nl
P106
P1153
7102633381
P21
P31
P496
0000-0003-2190-2444